Synta to Present at the Rodman & Renshaw Annual Global Investment Conference

Company to Webcast Presentation on September 13

LEXINGTON, Mass.--(BUSINESS WIRE)-- Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13 at 11:15 a.m. (ET) in New York.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.



CONTACT:

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125

KEYWORDS:   United States  North America  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.